Mankind Pharma Q1 Results FY26: Q1 PAT Narrows 18.30% to ₹438.32 Crore; Revenue Surged 24.50% YoY

Mankind PharmaQ1 Results FY26: Extracts of FY25 & FY26 (Consolidated Figures)

Particulars	Quarter Ended
	30-06-2025	30-06-2024
Revenue from Operations	₹3,570.35	₹2,867.85
Profit Before Tax (PBT)	₹926.65	₹770.96
Profit After Tax (PAT)	₹438.32	₹536.49

(Figures in crores)

Mankind PharmaQ1 Results FY26: Extracts of FY25 & FY26 (Standalone Figures)

Particulars	Quarter Ended
	30-06-2025	30-06-2024
Revenue from Operations	₹2,541.36	₹2,412.62
Profit Before Tax (PBT)	₹737.29	₹672.08
Profit After Tax (PAT)	₹412.76	₹476.42

(Figures in crores)

Mankind PharmaResults FY26 Highlights (Q1 FY26 vs FY25)

• Mankind Pharma clocked Q1 FY26 consolidated revenue of ₹3,570.35 crores vs ₹2,867.85 crores. 
• On the profit front, Mankind Pharma earned a consolidated PAT of ₹438.32 crore in Q1 FY26. During FY25, the company’s PAT stood at ₹536.49 crore. 
• Consolidated PAT fell for the first quarter of FY26, was 18.30% YoY, and revenue rose 24.50% YoY. 
• As per the standalone figures, the quarterly PAT of Mankind Pharma has decreased by 13.36% and revenue has increased by 5.34% YoY.

Mankind Pharma Share Price Performance

On the opening bell of 01st August 2025, the shares of Mankind Pharma opened at ₹2621.40 per share. However, the initial gains are sustained as of now, and Mankind Pharma shares are trading at ₹2,567.90 per share, lower than their opening price. 

Considering the long-term performance, Mankind Pharma shares have yielded close to 26.05% returns in the past 1 year, and 5-year returns stand at 97.60%. Over the maximum timeframe, the  Mankind Pharma share provided 97.48% returns to investors. However, one must ignore the risk of volatility in the stock market and invest in Mankind Pharma shares after thorough research. 

For regular stock updates, dividend alerts, and expert verdicts, stay informed with Univest!

Disclaimer: Investment in the share market is subject to risk. This news article is for informational purposes only. Conduct your own research before investing in shares and other securities.

Also Read : Piramal Pharma Q1 Results FY26: Q1 Loss Narrows 7.83% to ₹81.70 Crore; Revenue Fails 0.89% YoY

Recent Articles

Flysbs Aviation IPO GMP & Review: Apply or Avoid?

New India Assurance Company Q1 Results FY26: Q1 PAT Surged 67.29% to ₹400.33 Crore; Revenue Soared 10.26% YoY

Sri Lotus Developers IPO GMP: Day 1 IPO Live Updates

Varun Beverages Q1 Results FY26: Q1 PAT Surged 5.14% to ₹1,317.02 Crore; Revenue Dropped 2.33% YoY

Takyon Networks IPO GMP: Day 1 IPO Live Updates

Asian Paints Q1 Results FY26: Q1 PAT Plunged 6.00% to ₹1,099.77 Crore; Revenue Dropped 0.35% YoY